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ABSTRACT
INTRODUCTION Smoking is a substantial cause of premature death in patients 
with tuberculosis (TB), particularly in low- and middle-income countries 
(LMICs) with high TB prevalence. The importance of incorporating 
smoking cessation and tobacco-dependence treatment (TDT) into TB care 
is highlighted in the most recent TB care guidelines. Our objective is to 
identify the likely key facilitators of and barriers to smoking cessation for 
patients with TB in LMICs.
METHODS A systematic search of studies with English-language abstracts 
published between January 2000 and May 2019 was undertaken in the 
EMBASE, MEDLINE, EBSCO, ProQuest, Cochrane and Web of Science 
databases. Data extraction was followed by study-quality assessment and a 
descriptive and narrative synthesis of findings.
RESULTS Out of 267 potentially eligible articles, 36 satisfied the inclusion 
criteria. Methodological quality of non-randomized studies was variable; low 
risk of bias was assessed in most randomized controlled studies. Identified 
facilitators included brief, repeated interventions, personalized behavioural 
counselling, offer of pharmacotherapy, smoke-free homes and a reasonable 
awareness of smoking-associated risks. Barriers included craving for a 
cigarette, low level of education, unemployment, easy access to tobacco in 
the hospital setting, lack of knowledge about quit strategies, and limited 
space and privacy at the clinics. Findings show that the risk of smoking 
relapse could be reduced through consistent follow-up upon completion 
of TB therapy and receiving a disease-specific smoking cessation message.
CONCLUSIONS Raising awareness of smoking-related health risks in patients 
with TB and implementing guideline-recommended standardized TDT 
within national TB programmes could increase smoking cessation rates in 
this high-risk population.
ABBREVIATIONS BSS: behavioural support session, DOTS: directly observed treatment short-course (also known as TB-DOTS), 
HIC: high-income countries, HW: health workers, LHW: lay health workers, LMICs: low- and middle-income countries, 
MA: medical assistants, MI: motivational interviewing, NGO: non-governmental organisations, NRT: nicotine replacement 
therapy, RCS: randomized controlled studies, SCI: smoking cessation intervention, SCIDOTS: directly observed therapy short-
course plus smoking cessation intervention, SLT: smokeless tobacco, TB: tuberculosis, TDT: tobacco dependence treatment, 
WHO: World Health Organization.
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INTRODUCTION
The ‘dual epidemics’ of pulmonary tuberculosis (TB) 
and tobacco smoking are major global public health 
challenges faced especially by low- and middle-
income countries (LMICs)1,2. Tobacco smoking 
increases the risk of pulmonary TB infection, 
development of pulmonary TB and related mortality, 
and is closely associated with multi-drug resistant 
TB3. Smoking is positively associated with poor TB 
treatment outcomes, especially treatment failures and 
early deaths4.
Abstinence from smoking is essential for patients 
with TB. TB mortality rates drop substantially after 
quitting smoking5; interestingly, however, Jeyashree 
et al.6 did not find any randomized controlled 
trials to support the effect of smoking cessation 
on TB treatment outcomes. Two comprehensive 
practice and policy guidelines on tobacco cessation 
interventions within TB programmes were developed 
by the World Health Organization (WHO) and the 
International Union Against Tuberculosis and Lung 
Disease (IUATLD)1,3. These guidelines highlight the 
importance of incorporating professional tobacco-
dependence treatment (TDT) into TB care. While 
only about 4% of unassisted quit attempts in the 
general population are successful7, simple advice 
from a clinician to patients with TB who smoke has 
been shown to increase abstinence rates significantly 
(by 30%) compared to no advice1. Although in 
general populations, behavioural support combined 
with pharmacotherapy is the most effective strategy 
in helping people to quit, there is no evidence for 
the effectiveness of this strategy in TB patients who 
smoke. While medications are widely recommended, 
their costs prohibit their use in LMICs8.
A systematic review of the effectiveness of smoking 
cessation interventions among TB patients was already 
published, but little is known about the factors that 
affect smoking cessation and TDT in these patients. 
Thus, we conducted a narrative literature review with 
the main aim to identify facilitators and barriers that 
affect smoking cessation and TDT among people with 
TB in LMICs.
METHODS
Search strategy
A systematic search was conducted by the Institute of 
Scientific Information of the First Faculty of Medicine, 
Charles University in Prague, Czech Republic. The 
search was carried out in May 2019 and was followed 
by manual literature searches in the reference lists 
from the retrieved articles and through MEDLINE 
database to identify referenced articles and additional 
articles on smoking cessation in the TB context in 
LMICs9. Records were identified through searches in: 
1) Ovid–EMBASE and MEDLINE databases selected, 
2) EBSCO databases – Academic Search Complete 
database selected, 3) ProQuest, 4) Cochrane, 
and 5) Web of Science databases; and included 
articles published between January 2000 and May 
2019 according to the inclusion and exclusion 
criteria described below (see the search strategy 
in the Figure 1 flow diagram). Search terms and 
combinations thereof included: [facilitators OR 
barriers OR effectiveness OR success rate OR factors 
OR outcome(s) OR abstinence] AND [low-income 
countries OR middle-income countries OR specific 
countries according to the World Bank] AND [tobacco 
OR tobacco use cessation OR smoking OR smoking 
cessation OR treatment] AND [TB OR tuberculosis 
OR TB programme].
Research question
What are the facilitators and barriers for people with 
TB to quit smoking in LMICs?
Inclusion and exclusion criteria
Inclusion criteria of present review were: English-
language abstract of the article (irrespective of the 
language used in the main text), study population 
focused at people with TB in LMICs (according 
to the World Bank)9 who smoke (self-reported or 
biochemically validated smoking status) and were 
aged 15 years. We excluded studies on only smoking 
prevention and prevalence, those of not original 
research, and if no full text was available.
Study selection
The eligibility of studies was assessed using the 
inclusion criteria by two investigators (EK, KZ). A 
third investigator (AP) resolved any discrepancies in 
the opinions of the two investigators, checked by IN, 
and comments included from RH, HE, AS and KS. 
Data extraction and quality assessment 
Data extraction was conducted by one reviewer 
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to be subsequently discussed and checked by at 
least one other reviewer. Extracted data included 
the following items: author/year, country, study 
design, sample size, study purpose, findings, 
limitations, and quality assessment. Quality 
assessment was performed after data extraction 
and done independently by two reviewers (KZ, 
EK). Randomized controlled studies (RCS) were 
assessed using the Cochrane Risk of Bias tool for 
intervention studies10, non-randomized studies 
using the Newcastle-Ottawa Scale (NOS) and 
modified NOS adapted for cross-sectional studies11. 
Data synthesis and reporting
We descriptively summarised data and undertook a 
narrative synthesis of findings. PRISMA was used to 
inform reporting.
RESULTS
The initial search generated 267 potentially eligible 
articles after duplication removal, plus 72 records 
identified additionally by manual search (n=339) 
(Figure 1, PRISMA flow diagram)12. Only 36 
publications were deemed relevant for review after 
screening abstracts and full texts according to the pre-
specified inclusion and exclusion criteria. Of those 
papers excluded, 94.4% (286/303) reported only on 
tobacco or TB or LMICs separately, 11 (3.6%) were 
excluded for being prevention or prevalence studies, 
or for assessing smoking as a risk factor, with the 
remainder (2%) not being original research. 
Characteristics of eligible studies
Regarding design, the selected studies were 
prospective (including randomized controlled and 
Figure 1. PRISMA flow diagram illustrating the literature selection process
Studies included in narrative synthesis (n=36)
11 full-text articles excluded:
concerning only smoking prevalence 
and/or prevention, TB contacts, smoking as 
a risk factor 
Eligible full-text articles (n=47)
34 records excluded:
- 1 education series 
- 1 editorial
- 1 guidelines
- 2 protocols
- 29 reported only on tobacco or TB or 
LMIC separately (of which 4 reviews)
258 records excluded:
- 1 conference publication
- 257 reported only on tobacco or TB or LMIC 
separately (of which 35 reviews)
Additional 72 records identiied by manual 
research in the reference lists from the 
retrieved articles and through MEDLINE 
database
Records screened by title and abstract (n=267)
Duplicate records removed (n=12)
Records identiied through database searches in 
EMBASE (n=3), MEDLINE (n=100), EBSCO (n=13), Web of 
Science (n=60), Proquest (n=100), Cochrane (n=3) 
(n=279)
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non-randomized studies), cross-sectional studies, 
and qualitative studies. All studies but one (in 
French) were published in English. Eight of the 
included studies were RCS13-20, 28 articles reported 
on non-randomized studies21-48. Characteristics of 
the studies and their main findings are presented 
in Tables 1 and 2. Only one study recruited patients 
aged 15 years, with the participants of the other 
studies aged 18 years. Studies were conducted 
mainly in TB clinics, centres or units, health centres 
registered as diagnostic by TB program or provided 
DOTS services, respiratory clinics and, less often, in 
primary healthcare services. One study intervention 
was provided at home. In addition to smoking of 
cigarettes followed in all studies, 1 study included 
also rolled tendu or temburni leaf (bidi) smoking, 
2 studies a hookah session, and 7 studies the use of 
smokeless tobacco. Data extracted from the studies 
were reviewed to identify possible facilitators of and 
barriers to smoking cessation or TDT and relapse 
(Table 3). Table 4 shows factors associated with 
smoking relapse among TB patients.
Study quality
The inclusion criteria were met by 8 RCS, two of 
which were secondary analyses of data obtained 
from the selected studies (Table 1). Low risk of bias 
was assessed in 7 of 8 RCS (Table 5). The inclusion 
criteria were met by 28 non-randomized studies of 
variable methodological quality (Table 2).
Facilitators of smoking cessation/TDT in patients 
with TB of LMICs 
Facilitators of smoking cessation/TDT in patients with 
TB of LMICs are summarized in Table 3. 
The most frequently described facilitators that 
foster smoking cessation/TDT in TB patients were 
repeated brief interventions (including motivation 
and brochures)15-17,28,31 followed by personalized 
behavioural counselling incorporated into routine 
TB services24,35,43,46. The SCIDOT project showed 
that adding smoking cessation intervention (SCI) to 
conventional DOTS increased biochemically validated 
6-month abstinence24. RCS assessing behavioural 
intervention considered it an effective part of 
treatment increasing the success rate in quitting:
• The study of Louwagie et al.17 from South Africa 
reported higher efficacy of a brief motivational 
interviewing session (15–20 min) provided by 
lay healthcare workers (LHW) compared to only 
receiving standardized smoking cessation messages 
from a TB nurse and a smoking cessation booklet 
(control group).
• Smokers who received smoking cessation 
intervention (SCI) from a TB health visitor trained 
to deliver the ABC package (A=ask, B=brief advice, 
C=cessation support) were more likely to quit 
smoking compared to those who received existing 
standard of care in TB case management in India15.
• In the study by Kumar et al.16, the quit rate in 
the intervention group (physicians’ advice) was 
higher compared to the control group, but with no 
significant difference. However, the study evaluated 
only a 1-month abstinence period in a relatively 
small sample.
Three RCS studies confirmed the efficacy of 
combined interventions (behavioural support 
plus pharmacotherapy) in achieving longer-term 
abstinence at six months: 
• The ASSIST study compared the success rates in 
a group treated by behavioural support (30-min 
consultation to encourage patients to plan smoking 
cessation 1 week later, and a 10-min session 
to review progress) combined with 7 weeks of 
bupropion therapy (75 mg/day during week 1, and 
150 mg/day thereafter) to behavioural support only 
and usual care20. 
• A similarly combined intervention that included 
behavioural therapy plus medical treatment with 
bupropion 150 mg/day during week 1, increased to 
300 mg/day through week 9 led to success rates of 
71.7% vs 33.9% for the brief advice group vs 9.8% 
for a control group receiving only the short-course, 
directly-observed treatment (DOTS) regimen 
(p<0.001)13. 
• Biochemically verified quit rates were higher in the 
intervention arm (6 weeks of nicotine gum after 
which both arms received the same counselling) 
than in the control arm (47.8% vs 32.4%, p<0.001)19.
Two studies showed efficacy of repeated tobacco 
use intervention follow-up at a minimum of 6 months 
after end of TB treatment30,43.
In a secondary analysis of the ASSIST study20, Elsey 
et al.14 concluded that patients diagnosed with TB 
were more likely to be abstinent than those diagnosed 
with other respiratory conditions.
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Table 1. Summary of included randomized controlled studies concerning smoking cessation/TDT in patients with TB of LMICs (N=8)
Author, 
year
Location Study design Sample size/ age/sex/type of 
sample
Study purpose Findings Limitations
Aryanpur 
et al.13 
(2016)
Iran Randomized 
controlled study
n=183 newly-diagnosed 
(conirmed) patients who 
currently smoke with pulmonary 
TB, aged >18 years.
Setting: health centres 
implementing the Directly 
Observed Treatment Short Course 
(DOTS) strategy.
Success rate at 6 months. Combined intervention including individualized counselling sessions of 
quitting (behavioural therapy) plus medical treatment with slow- release 
bupropion can lead to a signiicant increase (71.7%) in the rate of 
continuous smoking cessation at the end of sixth months.
The outcome of smoking 
cessation was measured 
until the end of TB 
treatment.
Elsey et 
al.14 
(2015)
Pakistan Cluster 
randomized 
controlled study, a 
secondary analysis 
(data from the 
ASSIST trial)
n=1573 patients aged >18 years 
who were regular smokers of 
more than 1 cigarette or hookah 
session a day.
Setting: health centres registered 
as diagnostic centres by the TB 
program. 
To identify predictors of 
continuous and short-term 
abstinence, and continued 
smoking in patients suspected 
of TB.
A conirmed TB diagnosis was a signiicant predictor of continuous 
abstinence at 25 weeks, gender does not predict cessation, socio-familial 
context particularly at work may undermine smokers’  ability to achieve 
continuous abstinence, having a child at home was not a signiicant 
predictor of abstinence.
see Siddiqi et al.20 (2013) 
Goel et 
al.15 
(2017)
India Cluster 
randomized 
controlled study
n=152 sputum smear-positive 
pulmonary TB patients, aged 
t15 years, who were current and 
occasional smokers; 96.7% men, 
aged 30–44 years.
Setting: TB units
To assess treatment success (= 
the sum of cured, smear- or 
culture-negative patients in 
the last month of treatment) 
and to assess smoking 
cessation rates (patient had 
not smoked at all in the last 2 
weeks).
Difference in TB treatment outcome was found to be insigniicant between 
intervention (ABC intervention from TB health visitor) and control arm. 
Treatment success was higher among quitters (74.7%)  compared to smokers 
(25.2%), the difference was found to be signiicant (IRR=1.31; 95% CI: 
1.30–1.32; pd 0.0001). At the end of treatment, 57 (80.2%) patients in the 
intervention arm had quit smoking against 42 (57.5%) in the control arm. 
After adjusting for confounders, the relative risk of quitting during follow-
up was signiicantly higher in the intervention arm compared to the control 
arm for both PP analysis (adjusted IRR=1.56; 95% CI: 1.24–1.93; p<0.0001). 
Insigniicant difference in 
TB treatment outcome could 
be due to the fact that for 
an intervention to bring 
positive treatment outcome, 
the total time spent for each 
session should be relatively 
more than it was in the 
study. 
Kumar et 
al.16 
(2017)
India Randomized 
clinical study
n=73 patients aged >18 years, 
with TB and with a history of 
current smoking (80 with HIV 
infection and 80 with TB).
Setting: clinic
To determine the eficacy of 
physicians’ advice in addition 
to standard counselling 
compared with standard 
counselling alone in quitting 
smoking.
Among the patients with TB receiving physician’s advice using a modiied 
version of the 5As strategy for smoking cessation plus a brochure containing 
smoking cessation information with standard counselling, 44.4% (16/36) 
quit smoking, while 40.5% (15/37) quit smoking with counselling from the 
counsellors alone plus a brochure containing smoking cessation information 
(p=0.735).
Only a 1-month abstinence 
period was assessed.
Tob. Induc. Dis. 2020;18(August):67
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Author, 
year
Location Study design Sample size/ age/sex/type of 
sample
Study purpose Findings Limitations
Louwagie 
et al.17 
(2014)
South 
Africa
Randomized 
controlled 
intervention study
n=409 newly diagnosed adult 
patients with TB identiied as 
current smokers.
Setting: primary care public 
facilities
To determine the eficacy of 
brief motivational interviewing 
by lay health workers (LHW) 
in assisting TB patients with 
tobacco cessation in a setting 
with high HIV-TB coinfection 
rates.
Motivational interviewing (MI) by lay counsellors to promote smoking 
cessation in TB patients approximately doubled sustained biochemically 
veriied smoking abstinence for at least 6 months compared with brief 
advice alone [24/83 (28.9%) vs 11/83 (13.3%)].
MI was offered in only 
a single brief session by 
LHCWs. LHCWs delivered 
MI without monitoring 
by video-taping. Follow-
up measurement was not 
blinded. Pharmacotherapy 
was not offered to 
smokers because of local 
unavailability. Potential 
over-reporting of self-
reported quit rates.
Louwagie 
& Ayo-
Yusuf18 
(2015)
South 
Africa
A secondary 
analysis of 
results from 
the randomized 
controlled trial 
(Louwagie et al.17)
409 randomized patients, current 
smokers, being t18 years, being 
on TB treatment for less than one 
month.
Setting: primary care public 
facilities
To identify independent 
predictors of smoking 
cessation after adjusting for 
the intervention effect.
Smokers with high nicotine dependence were less likely to quit than those 
with low nicotine dependence during 1-month follow-up, but this effect 
was not sustained beyond this point in time. In multivariate analysis of the 
predictors of 7-day point prevalence abstinence during 1-month follow-up, 
motivational interviewing   intervention was signiicantly effective only for 
those with nicotine dependence  (OR=3.01; 95% CI: 1.74–5.21).
Potentially too small sample 
size to detect certain 
associations; self-reported 
smoking abstinence. 
Sharma et 
al.19 
(2018)
India Open-label, 
randomized 
controlled study
Eight hundred adult patients 
enrolled (>18 years) with newly 
diagnosed sputum-positive 
pulmonary TB with self-reported 
history of current cigarette/
rolled tendu or temburni leaf 
(bidi) smoking (more than 10 per 
day, every day for at least two 
months).
Setting: DOTS centres
Primary outcome = a change 
in the TB score at 24 weeks 
and sputum culture conversion 
at week eight. Secondary 
outcomes = time to sputum 
smear conversion, weight 
gain at 24 weeks, number 
of patients who have quit 
smoking at 24 weeks, and 
mortality at 24 weeks.
Although intervention of nicotine replacement treatment (NRT) (nicotine 
gum 2 mg for smokers up to 25 bidis/cigarettes/day or 4 mg for those 
smoking more for 6 weeks) combined with counselling achieved higher quit 
rates (47.8% versus 32.4% for control group) and a greater reduction in TB 
score was seen in intervention arm, TB score did not meaningfully change at 
8 and 24 weeks. Subsequent to treatment completion, most patients in both 
arms reported re-initiation of tobacco smoking (80.6% vs 79.7%).
The trial did not have a ‘drug 
treatment only’ arm without 
counselling. Also, the results 
of the study are ascribable 
to predominantly a single 
centre. The absent sputum 
production in a signiicant 
proportion of patients led 
to high loss to follow-up 
of the culture reports. 
Socioeconomic factors were 
not noted during the study.
Table 1. Continued
Continued
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Table 1. Continued
Author, 
year
Location Study design Sample size/ age/sex/type of 
sample
Study purpose Findings Limitations
Siddiqi et 
al.20 
(2013)
Pakistan Cluster 
randomized 
controlled study 
(the ASSIST trial)
n=1955 participants aged >18 
years who were regular smokers of 
more than 1 cigarette or hookah 
session a day with suspected 
pulmonary TB.
Setting: health centres registered 
as diagnostic centres by the TB 
program
Continuous CO-measured 
smoking abstinence at follow-
up at 1 month and 6 months.
Behavioural support session (BBS) alone or with bupropion (BBS+) was 
effective in achieving continuous abstinence at 6 months for BSS+ (RR=8.2; 
95% CI: 3.7–18.2), and for BBS alone (RR=7.4; 95% CI: 3.4–16.4).
Imbalances in the urban 
and rural proportions and 
smoking habits among 
treatment groups, inability 
to conirm adherence to 
bupropion treatment, and 
inability to validate longer-
term abstinence or the 
effect of smoking cessation 
on TB outcomes. 
Tob. Induc. Dis. 2020;18(August):67
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Table 2. Summary and quality assessment of included non-randomized studies concerning smoking cessation/TDT in patients with TB of LMICs (N=28) 
Author, year Country Study design Sample size/age/
sex/type of sample
Study purpose Findings Limitations Selection* Comparability* Outcome*
Amara et al.21 
(2008)
Morocco Comprehensive 
cross-sectional 
telephone 
survey
75 respiratory 
physicians working 
in TB diagnosis and 
monitoring centres; 
10.7% smokers 
(8/75), 58.7% men.
To evaluate attitudes and 
knowledge of Moroccan 
respiratory physicians towards 
smoking in the management 
of patients with TB and the 
feasibility of integrating smoking 
interventions into the national 
TB program.
Of these, 84% still reported 
smoking status in patients’ 
medical records.
66.7% of those interviewed by 
phone were certain that smoking 
increases the incidence of TB, 
96% believed that smoking 
would worsen the disease. More 
than 84% of the physicians 
inquired their patients about 
their smoking habits. Only 5.3% 
believed they were well trained 
to help smokers to stop.
Not reported *** *
Aryanpur et 
al.22 
(2016)
Iran Cross-
sectional study
Newly-diagnosed 
PTB patients aged 
t18 years; self-
reported smoking 
status; 248 (22%) 
patients were current 
smokers including 
228 (20.2%) daily 
smokers and 20 
(1.8%) occasional 
smokers.
Setting: health 
centre
To determine the intention to 
quit and its associated factors 
among smokers newly diagnosed 
with PTB.
When diagnosed with TB, 59 
smoker patients (23.8%) quit 
smoking. After PTB diagnosis, 
99 patients (52.4%) had the 
intention to quit in the next 
month. Living in urban areas, 
ofice jobs, being single and 
a one unit increase in the 
motivation scale signiicantly 
increased the intention to quit 
smoking.
Cross-sectional nature of this 
study does not allow evaluation 
of the causal relationship 
between factors and smoking 
cessation, and its prognostic 
factors. Thus, further prospective 
studies are required. Meanwhile, 
as this study was conducted on 
patients with newly diagnosed 
PTB, its results cannot be 
generalized to all TB patients.
** **
Continued
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Table 2. Continued
Author, year Country Study design Sample size/age/
sex/type of sample
Study purpose Findings Limitations Selection* Comparability* Outcome*
Awaisu et al.23 
(2010)
Malaysia Cross-
sectional study
n=817 newly 
diagnosed TB 
patients, 40.3% 
were smokers, 
13.9% ex-smokers; 
120 enrolled in the 
SCIDOTS project, 
98.7% were males.
Setting: TB clinics
To determine the prevalence of 
smoking among newly diagnosed 
TB patients and to evaluate 
the tobacco use knowledge 
and attitudes of those who are 
smokers in this population using 
a 58-item questionnaire.
Patients who were in the 
stage of contemplation/pre-
contemplation had signiicantly 
less knowledge than those in 
the preparation stage of change 
(3.73 vs 5.38; p=0.004). 65.1% of 
patients believed that smoking 
is fun and 61.3% that it calms 
nerves. 70.1% of respondents 
also agreed or strongly agreed 
that smoking makes them relieve 
all life stresses. However, 87.5% 
of patients agreed or strongly 
agreed that: smoking is a waste 
of money, 91.3% that tobacco 
use is very dangerous to health; 
and 81.3% that smokers are 
more likely to die from heart 
disease compared with non-
smokers.
The rates in  study might have 
been grossly underestimated 
due to the unknown smoking 
status of a reasonable proportion 
of the newly diagnosed TB 
patients who might as well be 
tobacco smokers. A trend of 
underestimation when smoking 
prevalence is based on self-
reports.
** **
Continued
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Table 2. Continued
Continued
Author, year Country Study design Sample size/age/
sex/type of sample
Study purpose Findings Limitations Selection* Comparability* Outcome*
Awaisu et al.24
(2011)
Malaysia Prospective 
non-
randomized 
controlled 
intervention 
(the SCIDOT 
project)
n=80 current 
smokers at the time 
of TB diagnosis; 40 
patients motivated 
to quit smoking (in 
preparation stage) 
received SCI in 
addition to DOTS (the 
intervention group 
and 46 unmotivated 
patients (in pre-
contemplation and 
contemplation 
stages) received 
conventional DOTS 
regimen (the usual 
care group). SCI 
= eleven sessions 
of individualized 
cognitive behavioural 
therapy with (60%) 
or without (40%) 
nicotine replacement 
therapy (nicotine 
gum 2 mg and 4 mg, 
nicotine transdermal 
patch, and nicotine 
inhaler).
Setting: respiratory 
clinics
To evaluate the impact of adding 
smoking cessation intervention 
(SCI) to conventional DOTS for 
TB on tobacco abstinence rates 
and TB treatment outcomes. 
Subjects in the DOTS group were 
more dependent on nicotine 
than those in the SCIDOTS group 
(FTND, 5.43 ± 1.96 vs 4.32 ± 
2.26; t = -2.439; p=0.017). At 
the end of 6-month follow-up, 
the one-month self-reported 
continuous abstinence rate, 
conirmed biochemically by both 
CO and saliva cotinine tests, 
was nearly 78% (31/40) in the 
intervention group versus 9% 
(4/46) in the usual care group 
(Pearson χ2=41.97; df=1; N=86; 
p<0.001).
The study compared persons 
motivated to quit smoking in an 
intervention group with those 
contemplating quitting smoking 
in a control group; therefore, the 
observed difference in smoking 
cessation between the groups 
would likely not have been so 
great.
**** * **
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Bam et al.25 
(2015)
Indonesia Cohort study n=750 new smear-
positive TB patients, 
82.3% male, 77.6% 
current smokers. 
Of the 80 healthcare 
facilities, 52 (65 %) 
were tobacco-free 
in March 2011, the 
number of which 
increased to 80 
(100%) by December 
2012. Smoking was 
not permitted in any 
buildings, grounds or 
carparks. Cigarettes 
were not sold, and 
tobacco advertising, 
promotion and 
sponsorship were 
not permitted on the 
premises.
Setting: health 
centres that provided 
DOTS services
To assess the implementation 
and effectiveness of the ABC 
smoking cessation approach 
for TB patients and the 
establishment of smoke-free 
environments in healthcare 
facilities and TB patients’ homes 
in Indonesia.
The point prevalence of the 
quit rate was 66.8% (389/582) 
at month 6. Predictors 
independently associated with 
quitting were the time from 
waking to the irst cigarette >30 
min, having a smoke-free home 
and the display of ‘no smoking’ 
signage at home at month 6. 
The ABC smoking cessation 
intervention was effective for: 
i) creating 100% tobacco-free 
health services, ii) promoting 
quitting smoking (66.8%), and 
iii) establishing smoke-free 
environments at home (86.1%).
Self-reporting of smoking status 
although the status of the 
patients’ smoking and of their 
smoke-free home were validated 
with a family member at month 
6. Issues of time constraints and 
high workload were raised at the 
initial training by the healthcare 
staff before the intervention; 
however, healthcare workers 
reported neither high workloads 
nor time constraints during the 
review meeting at months 2, 5, 
and 6.
*** * ***
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Boeckmann et 
al.26 
(2019)
Bangladesh 
and 
Pakistan
Qualitative 
study
n=6 healthcare 
workers in Pakistan 
and 2 in Bangladesh 
(5 men), ranging in 
age from 23 to 60 
years; n=35 patients 
(34 males), age 
ranging from 18 to 
60 years
Setting: clinics
Findings of a multi-country 
qualitative process evaluation 
assessing barriers to and 
facilitators of implementation 
of smoking cessation behaviour 
support in TB clinics in 
Bangladesh and Pakistan.
All patients report willingness 
to quit smoking and recent 
quit attempts. Individuals’ main 
motivations to quit include their 
health and the need to provide 
inancially for their family. 
Behavioural regulation such as 
avoiding exposure to cigarettes 
and social inluences from 
friends, family and colleagues 
are the main themes of the 
interviews. Most male patients 
do not feel shy admitting to 
smoking, for the sole female 
patient interviewee, stigma was 
an issue. Health workers report 
structural characteristics such as 
high workload and limited time 
per patient as primary barriers to 
offering behavioural support.
Sample size, gender bias *** ***
Brunet et al.27 
(2011)
South 
Africa
Cross-
sectional study
n=424 patients with 
suspected TB; mean 
age 39.5 (18–82) 
years, 67% male, 
71% black African, 
28% HIV infected, 
36% reported having 
previously suffered 
from TB, 65% current 
smokers and 17% 
had previously quit 
smoking.
Setting: clinics
1) To estimate the prevalence of 
tobacco smoking in patients with 
suspected TB; and 2) to measure 
the sensitivity and speciicity 
of their self-reported smoking 
status using plasma cotinine as 
the reference standard.
The prevalence of current 
smoking was estimated at 54% 
(95% CI: 49–58%) by plasma 
cotinine and 57% (95% CI: 
52–61%) by self-report. The 
sensitivity and speciicity of self-
reported smoking was 89% (95% 
CI: 84–93%) and 81% (95% CI: 
75–86%), respectively, using 
plasma cotinine as a reference 
standard.
Potential mis-classiication of 
exposure due to self-report. The 
use of cotinine concentration 
has its own limitations, including 
the detection of tobacco chewers 
and patients using NRT, and 
failure to detect those who had 
not smoked for >48 h.
*** ***
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Campbell et 
al.28 
(2014)
Nepal Prospective 
controlled 
intervention 
study
n=246 cigarette 
smokers with smear-
positive pulmonary 
TB, aged >16 years.
Setting: TB centre
Continuous abstinence for more 
than 6 months.
Brief simple (= advice given over 
approximately 10 min at the 
beginning of TB treatment by 
a staff member, repeated at 2 
and 5 months into TB treatment) 
resulted in a signiicant number 
(39%) quitting the habit 
for 6 months (CO-validated 
abstinence) vs 0% in a control 
group without gender difference.
Allocation to intervention or 
controls was not randomized. A 
further weakness was the delay 
of just over 2 years between the 
original training and start of 
enrollment, which arose mainly 
as a result of administrative 
problems.
** * ***
Deepak et al.29 
(2012)
India Community-
based, cross-
sectional study
n=202 former 
patients with TB who 
had completed TB 
treatment at least 
6 months before 
the interview; mean 
age 48 years; 52% 
(106/202) of users of 
any form of tobacco, 
33 smokers, 60 
smokeless tobacco 
(SLT) users, 13 both 
forms.
Setting: TB units
Semi-structured pre-tested 
interview schedule; abstinence, 
persistence and relapse rates at 
eight time-points in relation to 
diagnosis of TB and treatment 
completion were analyzed 
separately for SLT use and 
smoking.
The relapse rate of SLT use 
was much higher than that of 
smoking because most tobacco 
messages provided by doctors 
to patients were general in 
nature and focused on smoking. 
More tobacco and TB-speciic 
cessation messages need to be 
given to these patients.
Self-reported tobacco use. The 
indings of the study are not 
generalizable to all patients 
with TB since only patients who 
accessed TB units and completed 
treatment were studied.
*** **
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El Sony et al.30 
(2007)
Sudan Feasibility 
study
48 medical assistants 
(MA), all presented 
during the study; 
n=513 previously 
untreated male 
patients (new cases) 
who were enrolled 
in treatment for 
pulmonary TB were 
recruited (81% of 
current smokers in 
the intervention 
group vs 36% in the 
control group).
Setting: primary 
and respiratory care 
centres
To examine the feasibility 
of adding a simple cessation 
intervention to standard health 
care services for TB patients. 
A secondary question assessed 
the outcomes of tobacco 
cessation intervention by 
measuring reported tobacco 
use rates among patients in 
the intervention centres at the 
beginning and end of 12 months 
of follow-up.
According to baseline 
questionnaire given to 48 MA 
prior to the trial, 10 (21%) of the 
48 MA reported using some form 
of tobacco, with no signiicant 
difference between those in 
the control and intervention 
centres. Only 8% of participating 
MA reported that they did not 
allow smoking or snuff dipping 
(10%) at the health centre and 
22 (46%) reported almost always 
advising their patients about 
tobacco. Of all tobacco users 
who were followed up, reported 
cessation rates increased at each 
intervention. A 53.6% (165/308) 
abstinence rate at the end of 
TB treatment among those 
who were enrolled in a tobacco 
cessation program vs 14.3% 
(6/42) in a control group.
No biochemical validation of the 
reported high cessation rates.
**** * ***
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Gupte et al.31 
(2018)
India Mixed-
methods study
n=377 patients (84% 
men) with TB who 
were current tobacco 
users (12% smokers 
only, 78% SLT users 
only, 10% dual 
tobacco users); 25 
DOTS providers (80% 
women, mean age 38 
years) from 27 NGO-
run centres trained 
to provide brief 
advice and cessation 
support in line with 
Union guidelines49.
Setting: NGO-run 
DOTS centres
To determine: 1) the number 
of centres that started 
implementing brief tobacco 
cessation programs; 2) the 
characteristics of TB patients 
who were current tobacco users, 
stratiied by type of tobacco; and 
3) tobacco use status, stratiied 
by TB category, following 
tobacco cessation advice.
A progressive trend in quit 
rates was observed during the 
treatment period (32% among 
new patients and 15% among 
those on retreatment, although 
the quality of documentation 
related to the brief advice and 
cessation support provided by 
DOTS providers declined. DOTS 
providers also felt that they 
had acquired the necessary 
skills needed to implement the 
intervention and suggested 
important recommendations 
including refresher training 
courses, the possibility of 
referring dificult patients and/or 
people with multiple addictions 
to experts and the need to 
simplify documentation.
Self-reported tobacco use status, 
study design.
*** ***
Kanakia et al.32 
(2016)
India Cross-
sectional study
n=424 presumptive 
patients with TB 
aged >18 years, 
mean age 44 years 
(SD=16), smokers or 
smokeless tobacco 
users.
Setting: tertiary care 
hospital
To assess the burden of tobacco 
use among presumptive TB 
patients and their willingness 
to avail of tobacco cessation 
services at a tertiary care 
hospital.
41.5% (176/424) use tobacco 
in previous 1 month (95% CI: 
36.9–46.3%), 75% were smokers, 
25% SLT form; 53% were willing 
to avail themselves of tobacco 
cessation services, if provided; 
the willingness was higher 
among those who had attempted 
to quit and failed in the past 1 
year.
Not reported *** **
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Kaur et al.33 
(2013)
India Intervention 
study
n=2879 TB patients 
(81.7% with 
pulmonary TB), 
1986 males (69%), 
registered for DOTS 
treatment; 46.3% 
(1333/2879) of TB 
patients were current 
users of tobacco 
– smokers and/or 
smokeless tobacco 
users, 89.6% males, 
40.8% tobacco users 
resided in urban 
areas, and 52.2% 
were from rural 
areas.
Setting: primary 
healthcare services
The possibility and outcome of 
integrating incorporating ‘brief 
advice’ in tobacco cessation 
intervention in TB patients who 
are registered for treatment 
under a TB control programme 
and are tobacco users.
While 35.9% of the TB patients 
were smokers, 39.1% used 
smokeless tobacco. 61.9% of 
males and 54.3% of females 
expressed their willingness to 
quit. At the end of 6 months, 
67.3% of patients who were 
offered brief advice by the 
DOTS provider and the same 
advice was repeated during each 
interaction with the TB patient 
during the treatment period, 
quit tobacco, while 18.2% re-
lapsed and 14.5% were lost to 
follow-up.
The conirmation regarding 
quitting of tobacco use was 
subjective assessment based 
on the self-statement by the 
patients. It was not validated by 
performing tests such as urine 
cotinine or carbon monoxide 
analysis of breath.
*** **
Lam et al.34 
(2013)
South 
Africa
Cross-
sectional study
n=707 recently 
diagnosed TB 
patients, aged t18 
years and diagnosed 
with TB within the 
2 months prior to 
interview date; 46% 
men, 73% HIV-
infected; 6% (46) 
current smokers, 
38% (267) former 
smokers.
Setting: hospital
Assessed the current and recent 
smoking prevalence in those 
with TB and TB-HIV co-infection 
among hospitalized adults with 
recently diagnosed TB.
138 former smokers were 
reclassiied as current smokers 
upon reporting smoking within 
2 months before TB diagnosis, 
resulting in 26% of current 
smokers (184). By categorizing 
smoking status solely based 
on participants’ self-reported 
status at the time of interview, 
the group of participants 
who were current smokers 
but quit at symptom onset 
were misclassiied as former 
smokers, when in reality they 
were smoking at the onset of TB 
symptoms.
Not reported **** ***
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Lin et al.35 
(2015)
China Prospective 
study
n=244 patients with 
TB, current smokers 
from rural China.
Setting: public 
health TB clinics
To assess incorporation of 
smoking cessation intervention 
(providing information on the 
harmful effects of tobacco 
smoke and smoking and TB+ 
every follow-up visit with 
reinforcement health messages 
and advice to quit) into routine 
TB services.
A majority (81.6%) had made 
no attempt to quit before 
the diagnosis of TB, 95.9% of 
smokers were willing to quit. 
66.7% (156/244) reported 
abstinence at month 6 = remain 
abstinent at the end of TB 
treatment.
Findings may not be applicable 
to female smokers, as there were 
none in the study. Smoking 
status was based on self-report. 
20.1% of the TB patients 
assigned to the SCI were not 
seen at month 6. Lack of a 
control group.
*** **
Louwagie & 
Ayo-Yusuf36 
(2013)
South 
Africa
Cross-
sectional study
n=1926 [22% 
(420/1924) self-
reported smokers 
(37.6%) males] over 
18 years of age 
seeking TB treatment.
Setting: TB clinics
Semi-structured questionnaires About half (51.8%) of current 
smokers had previously 
attempted to quit in the past 12 
months (median quit duration 
21 days), but very few patients 
had made use of cessation aids 
or services.  The majority of 
respondents believed tobacco 
smoking was harmful for their 
health (90.5% were aware of 
the risk of lung cancer), but the 
level of awareness regarding the 
risk of stroke and heart attack 
was lower (48.5% and 38.2%, 
respectively), 40% noted that 
smokers were more likely to get 
TB and a third observed that 
smoking worsens TB, and were 
highly motivated to quit (median 
score 9).
The population of TB patients 
is not representative of all TB 
patients in the province or South 
Africa.
*** **
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Louwagie et 
al.37
(2019)
South 
Africa
Mixed-method 
study
n=45 patients with 
TB (82% men, mean 
age 39.8 years), 
who smoked, drank 
alcohol or did both, 
and had not been 
treated for TB for 
more than one 
month.
Setting: clinics
Semi-structured questionnaire 
to test the feasibility of the 
ProLife programme (a brief 
motivational intervention and 
SMS-programme) by monitoring 
idelity to MI sessions and 
assessing the proiciency of LHW 
in facilitating the MI sessions.
Multiple risk behaviour 
interventions similar to the 
ProLife programme can be 
effective and sequentially 
addressing smoking alongside 
other interventions as used 
in ProLife is preferable to 
simultaneous interventions. Most 
patients rated the MI sessions 
as helpful, ascribed positive 
attributes to their counselors, 
and reported behavioral changes. 
LHW: a) grasped the basic MI 
spirit but failed to understand 
speciic MI techniques due to 
insuficient speciic practice, b) 
viewed SMSs favourable, and 
c) considered limited space and 
privacy at the clinics as key 
challenges. 
Small sample size. Social 
desirability bias may have led to 
overly positive feedback from 
both LHW and TB patients: Self-
reported reductions in drinking 
and smoking were not validated.
**
Mariappan et 
al.38
(2016)
India A  
community-
based cross-
sectional study
n=235 patients with 
pulmonary TB; 83 
(35.3%) smokers at 
the time of diagnosis, 
23 (9.8%) used SLT.
Setting: primary 
health care centres
To assess the prevalence and 
pattern of tobacco use among 
pulmonary TB patients residing 
in urban Puducherry and to 
study the association of various 
sociodemographic factors with 
current tobacco smoking and 
current smokeless tobacco use.
30 patients quit smoking and 
22 patients reduced their 
smoking status after being 
diagnosed with TB and the rest 
37.3% (31/83) maintained their 
smoking status. Male patients 
and having lower education 
were signiicantly associated 
with current smoking during TB 
treatment.
Self-reported on tobacco use. ** **
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Navya et al.39
(2019)
India Mixed-
methods study 
including a 
quantitative 
(cohort study) 
n=413 patients; 
278 (67.3%) males, 
mean age 42.6 years; 
335 (81.1%) with 
pulmonary TB, 320 
(77.5%) new TB 
cases, smokers and/
or smokeless tobacco 
users.
Setting: TB units 
treated under 
Revised National 
Tuberculosis Control 
Programme
To: 1) report the extent of 
documentation of tobacco and 
alcohol usage data in the TB 
treatment card, and 2) explore 
the process, facilitators and 
challenges in the linkage of 
services for tobacco cessation 
and alcohol abuse from the 
perspective of health care 
providers and adult patients 
with TB.
The documentation of the 
tobacco use status was good but 
not universally done. Tobacco 
use was documented in 322 
(78%) of the TB treatment cards 
reviewed. Among the 86 (21%) 
patients documented as current 
tobacco users, 16 (19%) were 
linked to tobacco cessation 
services while no linkage was 
documented in the treatment 
cards of 46 (53.3%) patients.
All of the new TB treatment 
cards were not available for data 
collection in the few Tuberculosis 
Units of Dakshina Kannada 
district. This would have led to 
an over- or under-estimation 
of the results. Data could be 
validated for only a small subset 
of the total study population due 
to challenges in the two steps 
for obtaining informed consent.
** **
Ng et al.40
(2008)
Indonesia Cross-
sectional study
n=239 male TB 
patients who 
completed the DOTS-
based treatment 
regimen; 218 (91.2%) 
were ever smokers 
who had ever 
smoked even a puff 
of a cigarette.
Setting: lung clinics
Study: 1) documents smoking 
patterns among TB patients 
before diagnosis, during 
treatment and post treatment; 2) 
identiies messages that health 
professionals and DOTS providers 
give their patients about 
smoking; and 3) identiies factors 
associated with smoking relapse 
among TB patients.
Only 11% (n=8) remained daily 
smokers while on TB treatment. 
Relapsed smokers were 
signiicantly younger and started 
to smoke their irst cigarette 
earlier than quitters, more often 
than quitters perceived that 
smoking causes TB (p=0.01). 
Only one-third of ex-TB patients 
reported that they had been 
advised to quit smoking by a 
nurse, 69.2% received such 
advice from a doctor. Receiving 
a cessation message from one’s 
doctor was non-signiicantly 
associated with a lower 
likelihood of smoking relapse 
(OR=0.60).
Potential of recall bias when 
asking ex-TB patients about 
smoking levels. Our intention 
was to assess general levels of 
smoking at different points of 
time. Some of these former 
patients resumed smoking at the 
same levels as they did prior to 
illness, while others smoked at 
lower levels, mistakenly thinking 
that smoking at such levels is 
relatively safe. 
** ***
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Nichter et al.41 
(2016)
Indonesia Prospective 
two-arm 
intervention 
study
n=87 newly 
diagnosed male TB 
patients who smoked 
undergoing DOTS for 
TB at home.
Setting: home
To assess the impact of TB-
speciic quit smoking messages 
in the TB clinic and at home.
Although most patients with TB 
quit smoking when undertaking 
treatment, nearly a third resume 
smoking when treatment is 
completed and this percentage 
increases to 40% six months 
later. Many former patients 
and their family members do 
not consider low-to-moderate 
level smokers to be real smokers, 
particularly those who have 
reduced their smoking from one 
to two packs a day to just a few 
sticks.
Self-report; small sample size. *** * ***
Pradeepkumar 
et al.42 
(2008)
India Cross-
sectional study
n=215 patients with 
TB (males); mean 
age 49.0 years; 
94.4% (203/215) 
were ever tobacco 
users (smokers and/
or smokeless tobacco 
users).
Setting:  TB units
1) To document tobacco use 
patterns among TB patients at 
different time points before 
diagnosis, during treatment 
and following treatment; 2) to 
examine how often cessation 
messages are given to TB 
patients by health staff and 
DOTS providers; 3) to investigate 
how the messages received are 
understood; and 4) to identify 
critical points of time when 
cessation messages need to be 
given based on when relapse is 
most likely to occur.
79% quit within 1 week of 
diagnosis. During treatment 
period there were only 12.4% of 
persistent smokers and 87.6% of 
initial quitters of whom 64.2% 
stayed permanent quitters at 
the end of 6 months. Of the 48 
relapsed TB patients, one third 
relapsed within the irst 2–3 
months of treatment, another 
third within the next 3 months 
of treatment and 21% within 
the 3 months of treatment. More 
than half of all relapses occurred 
during the early months of 
treatment among patients whose 
DOTS providers were non-health 
staff.  Among patients who had 
DOTS providers who were health 
staff, most relapses occurred 
after completion of treatment.
The data are robust enough 
to support the conclusions 
about the need for: 1) repeated 
exposure of TB patients to 
smoking cessation intervention, 
and 2) interventions for former 
and quitting smokers to 
encourage sustained cessation.
** ***
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Sereno et al.43 
(2012)
Brazil Mixed-
methods study
n=16 DOTS providers 
and supervising 
physicians; 15/16 
women, mean 
age 45.8 years; 20 
patients, current 
smokers, completed 
the follow-up 
questionnaire and 
urine testing for 
cotinine. 
Setting: primary 
health care centres
A pilot study to determine 
whether DOTS workers could 
be trained to deliver smoking 
cessation counselling and 
referral interventions, to identify 
potential barriers to a full-scale 
randomized controlled trial on 
the effectiveness of integrated 
smoking cessation in DOTS, 
and to determine whether TB 
patients who smoke would agree 
to participate in such a program.
Their self-rated ability to 
communicate the 5 As improved 
signiicantly between pre-
training and post-training, and 
to provide smoking cessation 
support improved without 
statistical signiicance. There is a 
dose-response relation between 
the session length of person-to-
person contact and successful 
treatment outcomes. However, 
even minimal interventions 
lasting less than 3 min increase 
overall tobacco abstinence rates. 
Person-to-person treatment 
delivered for four or more 
sessions appears to be especially 
effective in increasing abstinence 
rates.
The conirmation regarding 
quitting of tobacco use was 
subjective assessment based 
on the self-statement by the 
patients. It was not validated by 
performing tests such as urine 
cotinine or carbon monoxide 
analysis of breath.
** *
Shangase et 
al.44 
(2017)
South 
Africa
Qualitative 
research 
design
20 inpatients (15 
men) at a TB hospital 
who self-identiied 
as smokers and had 
drug-resistant (DR) 
TB. Age ranged from 
18 to 70 years.
Setting: hospital
What are the barriers to 
smoking cessation among DR-TB 
inpatients in South Africa?
Using smoking as a coping 
mechanism was identiied as an 
addiction-related barrier (for 
more details, see Table 3). Lack 
of access to smoking cessation 
interventions is a key structural-
level barrier highlighted in this 
study.
This study recruited participants 
who were inpatients and were 
being treated for drug-resistant 
tuberculosis; therefore, the 
generalizability of the results to 
outpatients is limited.
*** ***
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Author, year Country Study design Sample size/age/
sex/type of sample
Study purpose Findings Limitations Selection* Comparability* Outcome*
Shin et al.45 
(2012)
China Qualitative 
study
Randomly selected 
hospitalized patients 
from an inpatient 
registration list and 
conveniently selected 
patients attending 
an outpatient clinic 
for screening, aged 
t18 years, had begun 
treatment for TB in 
the past 6 months, 
and had smoked 
any time during 
the 30 days prior to 
diagnosis with TB. 
Two focus group 
discussions of 17 
TB physicians and 
ive focus groups 
of 39 patients were 
conducted.
Setting: hospital
To compare perceptions about 
smoking cessation among TB 
patients and their physicians.
Patients who were advised to 
quit smoking by their physicians 
after diagnosis with TB were 
likely to progress in their stage 
membership and attempt to quit 
smoking. Patients and physicians 
were concerned about the 
likelihood of smoking relapse 
after patients recovered from 
TB. Physicians had low levels 
of knowledge regarding the 
effect of smoking on TB. Many 
doctors, particularly those who 
smoked, did not view smoking 
cessation as an integral part of 
TB treatment.
The focus groups were conducted 
in one TB hospital in Beijing, 
China. The indings may not be 
generalizable to TB patients and 
providers in other TB facilities. 
Many physicians, particularly 
those who were smokers, did 
not view smoking cessation as 
an integral part of TB treatment 
and did not believe that their 
patients would accept smoking 
cessation counselling.
* **
Siddiquea et 
al.46 
(2013)
Bangladesh Cohort study n=615 current 
smokers; 99% of 
men, mean age 38 
years (range 16–77); 
inal evaluation 
possible in 562 
patients.
Setting: peri-urban 
TB centres
To determine whether a modiied 
version of  The Union’s ABC 
guideline (5–10 min of brief 
advice to quit smoking) in 
Bangladesh was effective in 
promoting smoking cessation 
among TB patients and 
determinants associated with 
smoking cessation
Overall, 82% (464/562) of 
smokers had quit and the quit 
rate increased progressively 
from the irst follow-up to the 
end of TB treatment (usually 
at month 6 or 8). Patients were 
considered to have quit smoking 
if they reported that they had 
not smoked tobacco in the past 
15 days.
This was a pilot study and may 
have generated an exceptionally 
high level of enthusiasm for 
counselling that led to higher 
quit rates. Such enthusiasm may 
not be sustained over the long 
term if introduced more widely. 
Self-reporting of quitting. 
*** ***
Table 2. Continued
Continued
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Table 2. Continued
Author, year Country Study design Sample size/age/
sex/type of sample
Study purpose Findings Limitations Selection* Comparability* Outcome*
Tsai et al.47 
(2016)
Taiwan Cross-
sectional 
retrospective 
study
n=123 patients with 
TB at a rural district 
hospital (78% of 
men, mean age 61.4 
years, 45 [46.9%] 
smokers before TB 
diagnosis).
Setting: TB 
outpatient clinic in a 
local hospital
To evaluate and compare 
changes in cigarette smoking 
and health-promoting 
behaviours reported before and 
after TB diagnosis among adults 
in a disadvantaged region.
The percentage of participants 
who smoked decreased to 
30.2% (29/123) after receiving 
or completing TB treatment, 
determinants for current 
health-promoting behaviours 
were chronic disease (b= –0-.25; 
p=0.005) and completion of TB 
treatment (b=0.23; p=0.007). 
A high prevalence of cigarette 
smoking and low levels of 
health-promoting behaviours 
were observed before the 
diagnosis and during or after 
completing TB treatment.
Limited generalisability 
(relatively uneducated patients 
from rural hospital were 
recruited), design of the study 
and self-reporting of certain 
health-related behaviours.
** **
Warsi et al.48 
(2019)
Banglades, 
Nepal, and 
Pakistan
Mixed-
methods study
25 semi-structured 
interviews and 
12 Focus Group 
Discussion across 
Bangladesh, Nepal, 
and Pakistan, and 
administered the 
adapted a UK 
National Centre for 
Smoking Cessation 
and Training 
questionnaire to 
36 TB health workers 
(HWs) (100%  in 
Pakistan and 95% in 
Bangladesh did not 
smoke).
A brief behaviour support 
intervention (a lip book, a 
lealet and a poster) was tested 
with patients and health 
workers. Health workers received 
training in delivering a 
15–20 min intervention. 
Patients were not opposed to 
being approached about their 
smoking habit, although HW 
expressed concerns that women 
might not admit to tobacco use 
and that asking about tobacco 
use was a sensitive issue. HW 
ability to deliver tobacco 
cessation behavioural support 
to patients was hindered by 
a lack of knowledge about 
tobacco and TB interaction, 
low understanding of tobacco 
cessation, and poor patient 
communication skills. Additional 
barriers shown in Table 3.
Use of multiple data sources 
(health workers, policymakers 
and patients), multiple methods 
(focus groups, interviews and 
questionnaire) and drawing on 
the theoretical framework of 
COM-B to guide data collection 
and analysis. 
*** ***
* The Newcastle–Ottawa Scale (NOS) for Assessing the Quality of Nonrandomized Studies11.
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Table 3. Facilitators of and barriers to smoking cessation/TDT in patients with TB of LMICs identified in 
included studies
Facilitators
Conirmed TB diagnosis more likely than other respiratory conditions14
Living in urban areas, ofice jobs, being single signiicantly increased the intention to quit smoking22
Combined interventions13,19,20
Brief, but repeated interventions, motivation, brochures15-17,28,31
Tobacco-free healthcare facilities25
Time from waking to irst cigarette of >30 min, routine screening for smoking, having a smoke-free home and display of ‘no smoking’ 
sign at home, regular reminders and encouragement of by family members to quit smoking25
Willingness to quit – higher in those with previous attempt(s) in the past year32
Incorporating of training in brief advice into existing training of DOTS providers33
Personalized behavioural counselling incorporated into routine TB services24,35,43,46
High level of awareness regarding smoking risk for health36
Multiple risk behaviour interventions37
Repeated tobacco use intervention follow-up at a minimum of 6 months after end of TB treatment30,43
Providing intervention not only at a health facility but also on a daily basis at community level by health volunteers46
Barriers
High nicotine dependence18
Misclassiication of current smokers as former smokers at the time of TB diagnosis (= quit smoking at the onset of TB symptoms34)
Limited space and privacy at the clinics37
Male gender, lower education38
Daily smoking of more than 15 cigarettes/bidis at the time of diagnosis41
Patients’ cards without the provision to include about brief advice on smoking cessation given which has been mentioned in the TB 
treatment guidelines; lack of coordination between the TB treatment programme and tobacco cessation39,43
Identiied in patients with drug-resistant TB:
• Addiction-related personal barriers – initiating smoking as teenagers, craving for a cigarette, smoking as part of the daily routine, 
failed quit attempts (relapses when feeling better)
• Structural (institutional) factors – lack of impact of health education sessions, lack of extramural activities when on hospital 
admission, lack of access to smoking cessation interventions (unaware of any available aids to stop smoking or NRT), easy access to 
cigarettes within a hospital setting (from staff, peers, visitors, shops close to hospital, hospital café)44
• Non-addiction-related personal barriers – lack of knowledge about quit strategies, lack of willpower to quit, psychosocial stress, peer 
smokers’ inluence
Barriers for HW to provide BSS: institutional lack of resources (insuficient space, high patient load, no reporting/recording of tobacco, 
overwork) and an absence of professional support through monitoring and evaluation48
Possible barriers to smoking cessation/TDT  patients/staffs knowledge, attitudes
Lack of resources (human, inancial), low level of education of health providers on smoking cessation21
Beliefs that smoking is fun, calms nerves, relieves all life stresses23
Stigma (especially in women to admit using tobacco)26,48
Tolerance of smoking or snuff dipping at a health centre by medical assistants providing SCI, smoking staff30
Not considering low-to-moderate level smokers to be real smokers, particularly those who have reduced their smoking from one to two 
packs a day to just a few sticks41
Less knowledge that smoking increases risk of stroke and heart attack36
Physicians’ low levels of knowledge regarding the effect of smoking on TB – particularly physicians who smoked did not view smoking 
cessation as an integral part of TB treatment45
Decrease of initial enthusiasm for counselling (seen in pilot studies) over the long-term if introduced more widely46
Relying on the fact that the diagnosis of TB alone will lead to a more signiicant decrease in the prevalence of smoking among patient 
with TB47
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 Some smokers’ characteristics were found to be 
facilitators too: willingness to quit – higher in those 
with previous attempt(s) in the past year32, time 
from waking to the first cigarette of >30 min, having 
a smoke-free home, display of ‘no smoking’ sign 
at home25, and a high level of awareness regarding 
smoking risk for health36. Other identified facilitators 
were: living in urban areas, office jobs, and being 
single, which significantly increased the intention to 
quit smoking22.
Facilitators originating in the healthcare system 
were the following: incorporating training in brief 
advice into existing training of DOTS providers33, 
multiple risk behavior interventions37, and tobacco-
free healthcare facilities25. Finally, providing 
intervention not only at a health facility but also on 
a daily basis at community level by health volunteers 
facilitated smoking cessation46. 
Barriers to smoking cessation/TDT in patients 
with TB of LMICs
Barriers to smoking cessation/TDT in patients with 
TB of LMICs are presented in Table 3. 
Male gender, lower education, high nicotine 
dependence and daily smoking of more than 15 
cigarettes/bidis at the time of diagnosis, may be 
marked as non-influenceable risk factors that are 
negatively associated with success in smoking 
cessation/TDT18,38,42. Possible patients’ barriers to 
quit smoking may be less knowledge that smoking 
increases risk of cardiovascular diseases36 and their 
beliefs that smoking is fun and helps to deal with 
stress23.
The qualitative study of Shangase et al.44 conducted 
in patients with drug-resistant TB in South Africa 
found 2 categories of barriers to smoking cessation 
in patients with drug-resistant TB: 1) personal factors 
including addiction-related barriers (initiating smoking 
as teenagers, craving for a cigarette, smoking as part of 
the daily routine, failed quit attempts – relapses when 
feeling better) and non-addiction-related barriers (lack 
of knowledge about quit strategies, lack of willpower to 
quit, psychosocial stress, peer smokers’ influence); and 
2) structural (institutional) factors (lack of impact of 
health education sessions, lack of extramural activities 
when on hospital admission, lack of access to smoking 
cessation interventions (unaware of any available aids 
to stop smoking or NRT), easy access to cigarettes 
within a hospital setting (from staff, peers, visitors, 
shops close to hospital, hospital café). 
Table 4. Factors associated with smoking relapse among TB patients in LMICs (N=6) identified in included 
studies
Short duration of pharmacotherapy19
Socio-cultural inluences (i.e. family/friends smokers)26
Brief advice focused only on smoking could lead to a higher rate of SLT relapse seen as a form of harm reduction29
Receiving a disease-speciic cessation message – associated with a lower likelihood of smoking relapse40
Perception of low-moderate level smoking as harmless41
Period of follow-up: increase in relapses within the 6 months of treatment and within the 3–6 months following treatment40-42
Table 5. Risk of bias assessments assessed in randomized controlled studies 
Author, year Random 
sequence 
generation 
(selection 
bias)
Allocation 
concealment 
(selection 
bias)
Blinding 
participants/
personnel 
(performance 
bias)
Blinding 
outcome 
assessment 
(detection 
bias)
Incomplete 
outcome data 
(attrition 
bias)
Selective 
reporting 
(reporting 
bias)
Other bias
Aryanpur et al.13 (2016) Low Low Low Low Low Low Low 
Goel et al.15 (2017) Low Low Low Low Low Low Low 
Kumar et al.16 (2017) Low Low Low High Low Low High 
Louwagie et al.17 (2014) Low Low Low Low Low Low Low 
Sharma et al.19 (2018) Low Low Low Low Low Low Low 
Siddiqi et al.20 (2013) Low Low Low Low Low Low Low 
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Several barriers were connected to the healthcare 
system itself: limited space and privacy at the clinics37, 
lack of coordination between the TB treatment 
programme and tobacco cessation39,43, lack of 
resources (human, financial), low level of education of 
health providers on smoking cessation21, tolerance of 
smoking or snuff dipping at a health centre by medical 
assistants providing SCI, and smoking staff30. 
Regarding HW, barriers to provide BSS were as 
follows: institutional lack of resources (insufficient 
space, high patient load, no reporting/recording 
of tobacco, overwork), an absence of professional 
support through monitoring and evaluation48 or 
misclassification of current smokers as former smokers 
at the time of TB diagnosis (= quit smoking at the 
onset of TB symptoms)34. Low level of education of 
health providers on smoking cessation21, e.g. relying 
on the fact that the diagnosis of TB alone will lead 
to a more significant decrease in the prevalence of 
smoking among patients with TB47, and decrease 
of initial enthusiasm for counselling over the long-
term46, may be barriers to provide SCI.
Staff knowledge regarding the effect of smoking on 
TB, as well as attitudes to smoking cessation may have 
an impact in providing smoking cessation/TDT within 
TB care45,48. Shin et al.45 in their qualitative study 
pointed out that mainly those physicians who smoked 
did not view smoking cessation as an integral part of 
TB treatment. Other barriers were not considering 
low-to-moderate level smokers to be real smokers, 
particularly those who have reduced their smoking 
from one to two packs a day to just a few sticks41, and 
less knowledge that smoking increases risk of stroke 
and heart attack36. 
Another important barrier is mentioned in the 
Boeckmann et al.26 and Warsi et al.48 studies – asking 
about tobacco use was perceived a sensitive issue, 
especially among women who may not admit to 
tobacco use.
Table 4 shows factors associated with smoking 
relapse among TB patients in LMICs. Ng et al.40 
conducted qualitative interviews with TB patients 
and concluded that the majority of daily smokers 
quit smoking when diagnosed with TB; however, 
over one in three of those patients relapsed within 
6 months of TB treatment completion. Similarly, 
Pradeepkumar et al.42 and Nichter et al.41 found that 
most relapses occurred after completion of treatment. 
Short duration of pharmacotherapy might influence 
the number of patients who quit smoking, according 
to the randomized controlled study of Sharma et al.18. 
Possessing a disease-specific cessation message and 
focusing on all forms of tobacco use may decrease the 
probability of tobacco-dependence relapse29,40. 
DISCUSSION
Statement of principal indings
The studies included in this narrative literature 
review highlighted the feasibility and efficacy of 
incorporating brief advice as well as specialized 
treatment for smokers into TB care. Based on the 
findings from the selected studies and identification 
of factors affecting successful quitting, we propose 
a summary of implications for practice regarding 
smoking cessation or TDT in patients with lung TB 
in LMICs in the following paragraphs.
Tobacco-free TB centres and non-smoking staff are 
a condition sine qua non to support their patients 
in quitting. The centres’ staff members should 
have an opportunity to treat their potential tobacco 
dependence or not to smoke during their working 
hours (e.g. to reduce withdrawal symptoms by 
nicotine replacement therapy)25.
The staff should understand the importance of 
quitting smoking for TB prognosis, of providing 
brief interventions, of their own non-smoking status; 
regular refresher training session should be arranged 
and made available.
In TB centres, a brief, repeated and empathic 
intervention should be provided to all patients with 
TB who smoke. It is possible that a majority can quit 
smoking when diagnosed with TB40 or at the time of 
onset of TB symptoms34. Support for these patients 
should be part of routine care. They would benefit 
from regular monitoring of their withdrawal symptoms 
(WSs) and from an offer of pharmacotherapy in the 
case of intensive WSs, and brief support at each session 
within their respective TB centres. Motivational 
intervention should increase the number of patients 
quitting in the future. Empathic intervention increases 
the probability that the majority of patients will admit 
smoking. A potential gender barrier should also be 
taken into account26.
While it may seem unnecessary to measure CO 
levels in patients with suspected TB at the first 
consultation to verify their smoking status27, such a 
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strategy could help as bio-feedback for patients who 
are quitting.
All patients in TB centres who smoke should be 
educated, through a brief intervention, about the 
risks of smoking associated with their disease and 
the importance of the ‘not-even-one-puff’ rule, 
because a higher level of awareness implies a higher 
probability of quitting and a lower one a tendency 
to relapse36,40. Likewise, patients should be told that 
use of smokeless tobacco is a potential factor for 
smoking relapse29. Screening for smoke-free homes 
and recommendations to create them should be part 
of routine brief advice in smoking cessation. 
Health volunteers may play a most important role 
in daily provision of intervention outside of health 
facilities directly in patients’ communities46.
Tobacco-dependence treatment ranges from brief 
advice to intensive behavioural support together 
with pharmacological treatment7. It has been 
proven by RTCs that behavioural support combined 
with first-line pharmacotherapy (bupropion and 
nicotine replacement therapy) is effective in 
achieving prolonged abstinence at six months in 
adult TB patients participating in TB programmes 
in LMICs13,19,20. One of the possible less expensive 
pharmacotherapy options is cytisine, whose efficacy 
compares to that of currently licensed products. 
A study from Bangladesh8 may bring interesting 
findings; two face-to-face behavioural support 
sessions will be delivered and cytisine (active arm) or 
matching placebo (control arm) will be administered 
in a 25-day course. The success rate may depend 
on pharmacotherapy duration (at least 3 months) 
as well as on the type of intervention provided. A 
brief motivational session (15–20 min) and the 
ABC approach (A=ask, B=brief advice, C=cessation 
support) are more effective than only a smoking 
cessation message. The specialized TDT should be 
provided by a trained doctor, nurse, psychologist or 
another health care provider, with such a specialist 
ideally available in each TB centre49.
Several months’ follow-up after TB treatment 
completion with brief behavioural support and 
offer of pharmacotherapy in the case of a lapse or 
early relapse should be available as prevention of 
relapse in abstaining patients. A high number of 
patients relapsed 3–6 months after completion of TB 
treatment40,42. 
It is critical that national policymakers support 
effective tobacco control policies developed by the 
World Health Organization (WHO) Framework 
Convention of Tobacco Control (FCTC). According 
to the WHO MPOWER policy package, the main 
effective strategies designed to reduce the prevalence 
of tobacco use in the general population include those 
affecting the availability of tobacco products (taxes, 
advertising), minimizing exposure to tobacco smoke 
(smoke-free public indoor spaces without exception) 
and offering specialized help. Limiting bans on 
tobacco advertising and the ease of access to cheap 
tobacco, often in a single cigarette form, enhance 
barriers to quit50.
Limitations and strengths
Although we conducted quality assessment of eligible 
studies, this is not a systematic review. Heterogeneous 
study designs made it impossible to conduct a meta-
analysis and to assess the importance of individual 
factors in the quit process. However, this review maps 
and summarizes the available data on the topic, so 
that the formulated barriers and suggested facilitators 
can be identified for clinicians and policymakers 
to use. This summarized evidence could facilitate 
implementation of TDT in patients with TB in LMICs 
as an underused opportunity to significantly improve 
TB treatment outcomes and overall health.
Implications for policy, practice and research
Effective TDT provided by trained healthcare 
professionals is based on the same pillars, regardless 
of country or socioeconomic status. These include: 
a brief intervention as a routine part of healthcare; 
appropriately adapted information materials about the 
harmfulness of smoking in relation to TB and about 
the options in a smoking cessation programme; trained 
non-smoking staff in specialized centres; availability 
of pharmacotherapy; and regular follow-up. All these 
should be incorporated as a new standard into care of 
TB patients who smoke.
CONCLUSIONS
Raising awareness of the health risks of smoking 
in patients with TB as well as health providers and 
routine offer of tobacco-dependence treatment in 
established system of TB treatment in tobacco-free 
healthcare facilities may significantly contribute to 
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increasing the abstinence success rate in patients 
with TB. Due to its low current availability but high 
potential impact, it is crucial to consider TDT in 
patients with TB as a topic for future research.
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